Jazz Pharmaceuticals plc (NASDAQ: JAZZ) was indicated to open a bit weak on Tuesday ahead of the open on news that the company has announced an underwritten public offering of 7,883,366 of its ordinary shares. Unfortunately, all of the shares being sold are coming from existing holders so none of the proceeds will go back to Jazz’s coffers. While the company was quick to point out in the press release that the total number of ordinary shares outstanding will not change as a result of the offering. That doesn’t mean that the free float of shares will not change.
Book-runners are Barclays Capital and Citigroup Global Markets. Jazz shares are down only about 3% at $49.72 right before the open on thin volume and the 52-week trading range is $23.50 to $53.10. The pre-drop market capitalization was $2.9 billion versus the $390 million or so that will be raised by this offering.
ALERT: Take This Retirement Quiz Now (Sponsored)
Take the quiz below to get matched with a financial advisor today.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Take the retirement quiz right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
